ERAS — Erasca, Inc.
Is ERAS overbought or oversold? Here is the current MarketMoodz read.
Erasca, Inc. (ERAS) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Biotechnology) last closed at $13.89. The rating moved from Overbought to Oversold on November 16, 2026.
- Public ratingOversold (as of November 17, 2026)
- Last close$13.89
- Last changeMoved from Overbought to Oversold on November 16, 2026
- SectorHealthcare
- IndustryBiotechnology
See all oversold Healthcare stocks →
AI analysis
Erasca, Inc. is a small clinical‑stage oncology company whose valuation is driven largely by binary clinical and regulatory milestones. The company likely operates pre‑commercially and depends on external financing or strategic partnerships to fund development, creating dilution and runway sensitivity. Near‑term direction will hinge on upcoming program readouts or corporate developments; absent positive catalysts, the stock may trade in a consolidation range with elevated volatility. The most material upside scenarios involve successful late‑stage data or a partnership/M&A outcome, while downside scenarios include trial setbacks, funding shortfalls, or sector rotation away from small-cap biotech.
Key factors
- Clinical-stage pipeline with binary, outcome-driven catalysts (trial readouts, regulatory updates) that can meaningfully re-rate the equity
- Limited or no commercial revenue profile, implying dependence on capital markets and partnerships for funding
- High upside if clinical data are positive given oncology focus and potential for licensing/M&A interest from larger pharmas
- Current market tone is consolidative with selective support for growth names, providing a neutral near-term technical backdrop
- Sector themes favor large-cap pharma defensives, which may limit sustained risk-on flows into smaller specialty biotechs
- Distributor and specialty channel tailwinds for injectable therapies (broader sector theme) have limited direct relevance unless Erasca reaches commercialization or partners
Risks
- Clinical trial failure or safety/regulatory setbacks leading to sharp share-price declines
- Rapid cash burn and the need to raise capital, producing dilution risk for current shareholders
- Intense competition in oncology from better‑capitalized companies and established drug franchises
- Reimbursement and payer scrutiny if therapies reach late‑stage development, particularly around value/pricing
- Market illiquidity and volatility for small-cap biotech can amplify moves on limited news flow
- Macroeconomic or sector rotations away from small biotech into defensive large‑cap pharma could pressure multiple compression
See today's live rating, score and targets
Members see the live hourly rating for ERAS — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.